Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia
Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia
批准号:
9333033
负责人:
Surinder K. Batra
金额:
$37.38万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-06 至 2022-02-28
关键词:
Acinar CellAdenocarcinoma CellAffectAmylasesAnimalsApplications GrantsCRISPR/Cas technologyCell Cycle RegulationCell Differentiation processCell MaintenanceCellsChromatin StructureColon CarcinomaComplexDerivation procedureDevelopmentDiseaseDisease ProgressionDuct (organ) structureDuctalDuctal Epithelial CellExhibitsGenesGenetically Engineered MouseGoalsHumanInflammationInflammatoryKnock-outKnockout MiceKnowledgeLightLinkLiteratureMaintenanceMalignant neoplasm of pancreasMetaplasiaMetaplasticModelingMolecularMusMutationNeoplasm MetastasisNeoplastic Cell TransformationOncogenicOrganoidsPancreasPancreatic Ductal AdenocarcinomaPancreatic ductPancreatitisPathogenesisPatientsPhenotypePlayPolymerasePopulationPredispositionProcessPropertyProto-OncogenesRegulationRoleSamplingSeminalSomatic MutationStem cellsStructureSuppressor GenesTestingTissuesTransitional CellWorkbasebeta catenincancer stem cellcell typechronic pancreatitisembryonic stem cellhistone modificationknock-downmouse modelneoplasticnew therapeutic targetnoveloutcome forecastoverexpressionpancreas developmentself-renewalstem-like celltargeted treatmentthree dimensional cell culturetransdifferentiationtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Recent evidence has provided an understanding of the molecular mechanisms and genetic changes
underlying pancreatic ductal adenocarcinoma (PDAC) pathogenesis; however, limited information is available
on progression in the disease. Studies in several genetically engineered mouse models for PDAC suggest that
acinar cells, centroacinar cells, and/or postulated stem cells can be responsible for the development of
PDAC. This is believed to occur via a process termed “acinar-to-ductal metaplasia” (ADM), during which a
differentiated cell type (acinar) is reversibly replaced with another mature, differentiated cell type, a condition
also visible during inflammation, thereby underlining the predisposition of chronic pancreatitis patients to
PDAC. Pancreatic differentiation 2 (PD2), also known as polymerase associated factor-1 (Paf1), has been
found to be overexpressed in PDAC and to exhibit oncogenic potential. Our previous studies have further
defined the role of PD2/Paf1 in cell cycle regulation and in inducing chromatin structure remodeling in PDAC
cells. We have also demonstrated that PD2/Paf1 plays a major role in the multi-lineage differentiation of mouse
embryonic stem cells and maintains pancreatic cancer stem cells (PCSCs). Our preliminary efforts to
investigate the expression of PD2/Paf1 in KrasG12D;Pdx1Cre mouse model of PDAC showed that it is
differentially overexpressed in neoplastic pancreatic ducts during murine PDAC progression, as compared to
its strictly acinar expression in normal pancreas. PD2/Paf1 was specifically expressed in `intermediate
structures' expressing both acinar and ductal specific markers, representing `transitional cells' during
pancreatic acinar to ductal metaplasia. Further, we found that PD2/Paf1 is overexpressed along with PCSCs
markers in PDAC progression in mouse tissues and isolated CSCs. The multi-potent property of these CSCs
allows them to differentiate into several cell types. Therefore, the overall goal of this study is to define the role
of PD2/Paf1 in trans-differentiation of acinar cells to ductal cells during PDAC progression, through lineage-
differentiation of pancreatic CSC population. Based on these observations our central hypothesis is that
“PD2/Paf1 plays a significant role in the process of acinar-to-ductal metaplasia, thereby contributing to PDAC
progression, and its overexpression contributes to the ductal lineage-differentiation of pancreatic CSCs.” To
test this hypothesis, Aim 1 will focus on investigating the potential link of PD2/Paf1 in acinar-to-ductal
metaplasia using cerulein-induced mouse model of PDAC progression. Aim 2 will elucidate the mechanism(s)
of PD2/Paf1 in acinar-to-ductal metaplasia using acinar cells, organoid 3D-cultures, and PD2-/- animals. In Aim
3, we will understand the functional mechanism of PD2/Paf1 in ductal lineage-differentiation of pancreatic
CSCs in PDAC progression. Taken together, understanding of novel roles of PD2/Paf1 in ADM progression
through stem-like cell differentiation will lead to critical information for the long-term goal of developing novel,
targeted therapy against PDAC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
-
批准号:10683305
-
项目类别:
-
资助金额:$50.35万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
-
批准号:10557180
-
项目类别:
-
资助金额:$44.1万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Novel Therapy to Inhibit IPMN Progression
-
批准号:10446455
-
项目类别:
-
资助金额:$68.62万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer
-
批准号:10367553
-
项目类别:
-
资助金额:$46.42万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Novel Therapy to Inhibit IPMN Progression
-
批准号:10640955
-
项目类别:
-
资助金额:$65.59万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Connectivity mapping identified novel combination therapy for glioblastoma
-
批准号:10504826
-
项目类别:
-
资助金额:$44.59万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Connectivity mapping identified novel combination therapy for glioblastoma
-
批准号:10686268
-
项目类别:
-
资助金额:$43.7万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer
-
批准号:10503433
-
项目类别:
-
资助金额:$52.69万
-
财政年份:2022
-
负责人:Surinder K. Batra
-
依托单位:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
-
批准号:10156494
-
项目类别:
-
资助金额:$63.74万
-
财政年份:2021
-
负责人:Surinder K. Batra
-
依托单位:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
-
批准号:10339431
-
项目类别:
-
资助金额:$62.64万
-
财政年份:2021
-
负责人:Surinder K. Batra
-
依托单位:
Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer
-
批准号:10551280
-
项目类别:
-
资助金额:$62.24万
-
财政年份:2021
-
负责人:Surinder K. Batra
-
依托单位:
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer
-
批准号:10543148
-
项目类别:
-
资助金额:$53.54万
-
财政年份:2019
-
负责人:Surinder K. Batra
-
依托单位:
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer
-
批准号:9917334
-
项目类别:
-
资助金额:$61.45万
-
财政年份:2019
-
负责人:Surinder K. Batra
-
依托单位:
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer
-
批准号:10308404
-
项目类别:
-
资助金额:$53.54万
-
财政年份:2019
-
负责人:Surinder K. Batra
-
依托单位:
Core 1: Administrative and Bioinformatics Core
-
批准号:10413941
-
项目类别:
-
资助金额:$24.81万
-
财政年份:2018
-
负责人:Surinder K. Batra
-
依托单位:
Pancreatic Cancer Metastasis
-
批准号:10413937
-
项目类别:
-
资助金额:$161.14万
-
财政年份:2018
-
负责人:Surinder K. Batra
-
依托单位:
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis
-
批准号:10413938
-
项目类别:
-
资助金额:$30.89万
-
财政年份:2018
-
负责人:Surinder K. Batra
-
依托单位:
Pancreatic Cancer Metastasis
-
批准号:10203861
-
项目类别:
-
资助金额:$164.43万
-
财政年份:2018
-
负责人:Surinder K. Batra
-
依托单位:
Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis
-
批准号:10203862
-
项目类别:
-
资助金额:$31.53万
-
财政年份:2018
-
负责人:Surinder K. Batra
-
依托单位:
Core 1: Administrative and Bioinformatics Core
-
批准号:10203865
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2018
-
负责人:Surinder K. Batra
-
依托单位:
海外基金